MARKET

ACHV

ACHV

Achieve
NASDAQ

Real-time Quotes | Nasdaq Last Sale

9.93
-0.30
-2.93%
After Hours: 9.78 -0.15 -1.51% 18:48 04/16 EDT
OPEN
10.35
PREV CLOSE
10.23
HIGH
10.49
LOW
9.64
VOLUME
134.93K
TURNOVER
--
52 WEEK HIGH
18.26
52 WEEK LOW
6.60
MARKET CAP
61.07M
P/E (TTM)
-2.4641
1D
5D
1M
3M
1Y
5Y
Achieve Announces Publication of the ORCA-1 Phase 2b Clinical Trial of Cytisinicline in Adult Smokers in Nicotine and Tobacco Research
ACCESSWIRE · 4d ago
Achieve Life's cytisinicline shows efficacy in smoking cessation treatment
Achieve Life Sciences (ACHV) announces results from Phase 2b ORCA-1 trial in scientific journal Nicotine and Tobacco Research. ORCA-1 evaluated the efficacy and safety of cytisinicline across various dosing schedules
Seekingalpha · 4d ago
Achieve Announces Publication Of The RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) In Addiction
Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine addiction, today announced
Benzinga · 03/25 10:11
Achieve Announces Publication of the RAUORA Head-to-Head Non-Inferiority Clinical Trial Comparing Cytisinicline and Chantix(R) (varenicline) in Addiction
Subjects treated with cytisinicline were 55% more likely to quit smoking at 6 months and experienced significantly fewer side effects compared to those who received varenicline
ACCESSWIRE · 03/25 09:30
ACHV: Fourth Quarter and Full Year 2020 Results
Zacks Small Cap Research · 03/22 13:30
Achieve Life Sciences to Participate in M-Vest and Maxim Group Inaugural Emerging Growth Virtual Conference
Presenting Innovative Small and Mid-Cap Companies in Healthcare, Industrials, Electric Vehicles, TMT, and Consumer Products
ACCESSWIRE · 03/16 09:30
Achieve Life Sciences Announces Appointment of Dr. Bridget Martell and Dr. Cindy Jacobs to Board of Directors
SEATTLE, WA and VANCOUVER, BC / ACCESSWIRE / March 15, 2021 / Achieve Life Sciences, Inc. (NASDAQ:ACHV), a clinical-stage pharmaceutical company committed to the global development and commercialization of cytisinicline for smoking cessation and nicotine a...
ACCESSWIRE · 03/15 11:30
Ladenburg Thalmann & Co. Maintains Their Buy Rating on Achieve Life Sciences (ACHV)
In a report released today, Michael Higgins from Ladenburg Thalmann & Co. maintained a Buy rating on Achieve Life Sciences (ACHV), with a price target
SmarterAnalyst · 03/12 11:45
More
Forecast
Actual (USD)
Estimate (USD)
Income StatementMore
Net Income (USD)
YoY (%)
Balance SheetMore
Total Assets (USD)
Total Liabilities (USD)
Debt to Asset (%)
Cash FlowMore
Operating (USD)
YoY (%)
Learn about the latest financial forecast of ACHV. Analyze the recent business situations of Achieve through EPS, BVPS, FPS, and other data. This information may help you make smarter investment decisions.
Analyst Rating

Based on 4 analysts

Buy

Disclaimer: The analysis information is for reference only and does not constitute an investment recommendation.

Analyst Price Target
The average ACHV stock price target is 45.20 with a high estimate of 100.00 and a low estimate of 21.00.
EPS
Institutional Holdings
Institutions: 40
Institutional Holdings: 1.15M
% Owned: 18.77%
Shares Outstanding: 6.15M
TypeInstitutionsShares
Increased
4
21.59K
New
6
109.78K
Decreased
3
30.79K
Sold Out
3
60.17K
  • Performance
  • Asset Allocation
  • Dividend History
No Data
Industry
Biotechnology & Medical Research
+0.60%
Pharmaceuticals & Medical Research
+0.89%
Key Executives
Chairman/Executive Director
Richard Stewart
President/Director
Cindy Jacobs
Chief Executive Officer/Director
John Bencich
Chief Accounting Officer
Jerry Wan
Chief Scientific Officer
Anthony Clarke
Director
Scott Cormack
Director
Bridget Martell
Independent Director
Donald Joseph
Independent Director
Martin Mattingly
Independent Director
Jay Moyes
Independent Director
H. Stewart Parker
No Data
About ACHV
Achieve Life Sciences, Inc. is a clinical-stage pharmaceutical company engaged in the development and commercialization of cytisine for smoking cessation. The Company’s focus is to address the global smoking health epidemic, which is the leading cause of preventable death and is responsible for nearly six million deaths annually worldwide. Cytisine is an established 25 day smoking cessation treatment that has been approved and marketed in Central and Eastern Europe by a third party for over 20 years under the brand name TabexTM. As of December 2016, it is estimated that over 21 million people have used cytisine to help combat nicotine addiction, including over 2,000 patients in investigator-conducted, Phase III clinical trials in Europe and New Zealand.

Webull offers kinds of Achieve Life Sciences Inc stock information, including NASDAQ:ACHV real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, ACHV stock news, and many more online research tools to help you make informed decisions.

You can practice and explore trading ACHV stock methods without spending real money on the virtual paper trading platform.